MAY 7·GlobeNewswire→
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma, Inc. announced inducement equity awards to seven new employees, including its new president and CEO, Shao-Lee Lin, M.D., Ph.D. These grants, comprising stock options and restricted stock units, were approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. Dr. Lin received options to purchase 655,074 shares and 327,537 restricted stock units, while the other six employees received options for 518,599 shares and 327,534 restricted stock units in aggregate.
MAY 1·GuruFocus→
Cue Biopharma (CUE) Secures $30M in Private Placement Financing
Cue Biopharma Inc. (CUE) has announced a private placement financing expected to generate $30 million in gross proceeds from accredited investors. This strategic move aims to strengthen the company's financial position and fund ongoing research and development in the biotechnology sector. Despite a moderate GF Score™ of 52, Cue Biopharma faces challenges with low profitability and financial strength, prompting investors to carefully consider these factors alongside its rapid revenue growth and potential undervaluation based on its price-to-sales ratio.
